Brief: Xencor And Bristol Myers Squibb Enter License Agreement For Use Of Xtend Xmab Technology In SARS-COV-2 Neutralizing Monoclonal Antibody Combination For Treatment Of COVID-19

Xencor

25/05/2021 13:30

May 25 (Reuters) - Bristol-Myers Squibb Co  BMY.N :
    * XENCOR AND BRISTOL MYERS SQUIBB ENTER LICENSE AGREEMENT
FOR USE
OF XTEND™ XMAB® TECHNOLOGY IN SARS-COV-2 NEUTRALIZING MONOCLONAL
ANTIBODY COMBINATION FOR THE TREATMENT OF COVID-19
    * XENCOR - BRISTOL MYERS WILL HAVE SOLE RESPONSIBILITY FOR
SUPPORTING & ADVANCING RESEARCH, DEVELOPMENT, REGULATORY,
COMMERCIAL ACTIVITIES FOR SARS-COV-2 MAB DUO
    * XENCOR INC - BRISTOL MYERS WILL HAVE NON-EXCLUSIVE ACCESS
TO
XENCOR'S XTEND FC TECHNOLOGY

Source text for Eikon:  ID:nBw1NZJMxa 
Further company coverage:  BMY.N 

 ((Reuters.Briefs@thomsonreuters.com;))